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Abstract
Background: Recurrences are reported in 70% of all patients after resection of colorectal liver metastases (CRLM), in
which half are confined to the liver. Adjuvant hepatic arterial infusion pump (HAIP) chemotherapy aims to reduce the risk
of intrahepatic recurrence. A large retrospective propensity score analysis demonstrated that HAIP chemotherapy is
particularly effective in patients with low-risk oncological features. The aim of this randomized controlled trial (RCT) --the
PUMP trial-- is to investigate the efficacy of adjuvant HAIP chemotherapy in low-risk patients with resectable CRLM.
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Methods: This is an open label multicenter RCT. A total of 230 patients with resectable CRLM without extrahepatic
disease will be included. Only patients with a clinical risk score (CRS) of 0 to 2 are eligible, meaning: patients are allowed
to have no more than two out of five poor prognostic factors (disease-free interval less than 12months, node-positive
colorectal cancer, more than 1 CRLM, largest CRLM more than 5 cm in diameter, serum Carcinoembryonic Antigen above
200 μg/L). Patients randomized to arm A undergo complete resection of CRLM without any adjuvant treatment, which is
the standard of care in the Netherlands. Patients in arm B receive an implantable pump at the time of CRLM resection
and start adjuvant HAIP chemotherapy 4–12 weeks after surgery, with 6 cycles of floxuridine scheduled. The primary
endpoint is progression-free survival (PFS). Secondary endpoints include overall survival, hepatic PFS, safety, quality of life,
and cost-effectiveness. Pharmacokinetics of intra-arterial administration of floxuridine will be investigated as well as
predictive biomarkers for the efficacy of HAIP chemotherapy. In a side study, the accuracy of CT angiography will be
compared to radionuclide scintigraphy to detect extrahepatic perfusion. We hypothesize that adjuvant HAIP
chemotherapy leads to improved survival, improved quality of life, and a reduction of costs, compared to resection alone.
Discussion: If this PUMP trial demonstrates that adjuvant HAIP chemotherapy improves survival in low-risk patients, this
treatment approach may be implemented in the standard of care of patients with resected CRLM since adjuvant systemic
chemotherapy alone has not improved survival.
Trial registration: The PUMP trial is registered in the Netherlands Trial Register (NTR), number: 7493. Date of registration
September 23, 2018.
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Background
Colorectal cancer (CRC) is the third most common cancer
in the Netherlands. More than half of patients with CRC
will eventually develop colorectal liver metastases
(CRLM), of whom 25% have resectable disease at first
presentation [1]. Most patients develop recurrent disease
after curative intent resection of CRLM, which in about
50% of patients is confined to the liver [2]. A large phase
III trial investigating perioperative systemic chemotherapy
for patients with resectable CRLM found overlapping
survival curves: 5-year overall survival (OS) was 51% with
perioperative chemotherapy versus 48% with surgery
alone (p = 0.34) [3, 4]. Therefore, resection without add-
itional chemotherapy is currently the standard of care in
the Netherlands and better adjuvant treatment is needed.
The risk of recurrence can be predicted with the clin-
ical risk score (CRS) [5]. The CRS is the sum of five poor
prognostic factors: disease-free interval less than 12
months, node-positive CRC, more than one CRLM, lar-
gest CRLM over 5 cm in diameter, and serum carci-
noembryonic antigen (CEA) level above 200 μg/L. After
assigning one point to each of the five risk factors,
patients can be stratified into low-risk (0–2 points) and
high-risk (3–5 points) of recurrence.
Hepatic arterial infusion pump chemotherapy
Hepatic arterial infusion pump (HAIP) chemotherapy
using floxuridine for liver tumors is a treatment that has
been developed at Memorial Sloan Kettering Cancer Cen-
ter (MSKCC, New York, USA). It is currently not available
in the European Union (EU), because floxuridine (FUDR)
is not registered in the EU. The biological rationale for
intra-arterial treatment is that the hepatic artery rather
than the portal vein is responsible for most of the blood
supply to liver tumors [6, 7]. Intra-arterial floxuridine is
delivered in the hepatic artery via a surgically implantable
pump with a catheter in the gastroduodenal artery. Up to
95% of floxuridine is extracted by the liver during the
first-pass, allowing an up to 400-fold increase in hepatic
exposure with minimal systemic exposure [8, 9]. The
pump is filled percutaneously and the liver is continuously
perfused with chemotherapy.
Promising results of HAIP chemotherapy have been
reported. A randomized controlled trial (RCT) dem-
onstrated superior 2-year overall survival (OS) of 85%
in patients with resectable CRLM treated with HAIP
and concurrent systemic chemotherapy (5-FU) com-
pared to 69% in patients with resection and systemic
chemotherapy (5-FU) only (p = 0.02) [10]. A recent
retrospective analysis evaluated 2368 consecutive pa-
tients undergoing complete resection of CRLM with
and without adjuvant HAIP chemotherapy at MSKCC
between 1992 and 2012 [11]. The median OS with
HAIP chemotherapy was 67 months versus 44 months
without HAIP chemotherapy (p < 0.001). After adjust-
ing for seven independent prognostic factors in multi-
variable analysis, the hazard ratio (HR) of HAIP
chemotherapy was 0.67 (95% CI: 0.59–0.76, p < 0.001)
[11]. The median OS in the group without HAIP
chemotherapy was similar to the 45 months found in
a series of 2715 patients from the UK where no
HAIP chemotherapy was used [12]. Subgroup analyses
demonstrated that HAIP chemotherapy is particularly
effective in low-risk patients (median OS 89 months
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versus 53 months, p < 0.001). In high-risk patients
however, the difference in median OS was still statis-
tically significant and clinically relevant, however, less
pronounced (50 months versus 37 months, p < 0.001)
[13].
Methods/design
Objective
The primary aim is to compare the progression-free sur-
vival (PFS) of surgery with adjuvant HAIP chemotherapy
to surgery alone in patients with resectable CRLM with
a low CRS 0–2 points). Secondary objectives are to com-
pare OS, postoperative complications, adverse events,
quality of life, and costs between the two arms. Pharma-
cokinetics of intra-arterial administration of floxuridine
will be investigated as well as predictive biomarkers for
the efficacy of HAIP chemotherapy. In a side study, the
accuracy of CT angiography will be compared to radio-
nuclide scintigraphy to detect extrahepatic perfusion.
Study design
The PUMP trial is a phase III randomized controlled
open label, multicenter trial to compare the combined
efficacy of resection and/or open ablation and adjuvant
HAIP chemotherapy to resection and/or open ablation
alone in patients with CRC and resectable CRLM with a
low CRS (0–2 points). This trial started in August 2018.
Five centers participate in this study (Erasmus MC Can-
cer Institute, Rotterdam; Antoni van Leeuwenhoek,
Amsterdam; Academic Medical Center, Amsterdam;
Universitary Medical Center Utrecht, Utrecht; IJsselland
Hospital, Capelle aan den IJssel). Patients will be
randomized in a 1:1 ratio (Fig. 1) to resection of CRLM
only (arm A), or resection of CRLM with adjuvant HAIP
chemotherapy (arm B). Stratification factors will be cen-
ter, number of CRLM (< 4 or ≥ 4 CRLM), and size of the
largest CRLM (< 5 cm or ≥ 5 cm). Blinding is not feasible
because of the nature of the intervention, including a
visible subcutaneous pump. In patients who received
preoperative chemotherapy for CRLM, the CRS values
prior to start of preoperative chemotherapy should be
used to determine eligibility. A computed tomography
(CT) scan in (early) arterial phase of the liver is required
prior to inclusion to determine whether intra-arterial
catheter placement is technically possible. The multidis-
ciplinary meeting should determine that complete resec-
tion of the CRLM is feasible. Resectability is defined as
the opportunity to achieve an R0 resection with a suffi-
cient liver remnant. Randomization will be performed
preoperatively if the participant meets all the criteria.
Study population
Adults with resectable CRLM without extrahepatic dis-
ease (EHD) and a low CRS (0–2 points) will be consid-
ered for inclusion.
Patients are eligible for this study when they meet the
following inclusion criteria:
 age ≥ 18 years;
 ECOG performance status 0 or 1;
 histologically confirmed CRC;
 radiologically confirmed CRLM, amenable for local
treatment (resection or open ablation);
INCLUSION
PRE-OPERATIVE RANDOMIZATION
RESECTION CRLM
< 6 weeks
ARM A: FOLLOW-UP ARM B: HAI pump implantation
HAIP chemotherapy: 6 cycles of 4 weeks 
4-12 weeks
Excluded during surgery, if: 
- Extrahepatic disease 
- Unresectable CRLM*
*Complete resection in one-stage is not possible
Fig. 1 Study flow-chart
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 CRS of 0–2. In patients with unknown nodal status
of the CRC (in patients with synchronous resection
of CRC and CRLM), the nodal status is counted as
zero;
 positioning of a catheter for HAIP chemotherapy is
technically feasible based on an early arterial phase
CT angiography (CTA) (1 mm slide thickness);
 adequate bone marrow, liver, and renal function as
assessed by the following laboratory requirements to
be conducted within 15 days prior to randomization:
absolute neutrophil count (ANC) ≥1.5 × 109/L,
platelets ≥100 × 109/L, Hb ≥5.5 mmol/L, total
bilirubin ≤1.5 upper normal limit (UNL), ASAT ≤5
x UNL, ALAT ≤5 x UNL, alkaline phosphatase ≤5 x
UNL, (calculated) glomerular filtration rate (GFR)
>30 mL/min;
 written informed consent.
A potential subject who meets any of the following cri-
teria will be excluded from participation in this study:
 presence of EHD, including positive portal lymph
nodes, at the time of liver resection or any time
since CRC diagnosis, with exception of small (≤ 1
cm) extrahepatic lesions which are not clearly
suspicious of metastases (e.g., pulmonary lesions
that are too small to characterize);
 second primary malignancy except in situ carcinoma
of the cervix, adequately treated non-melanoma skin
cancer, or other malignancy treated at least 5 years
prior to inclusion without evidence of recurrence;
 prior hepatic radiation, resection, intra-arterial ther-
apy or ablation;
 CRLM requiring two-staged liver resections;
 liver-first resections; but simultaneous resection of
CRC and CRLM is not an exclusion criterion;
 (partial) portal vein thrombosis;
 known DPD-deficiency (heterozygous or homozy-
gous of DPYP);
 pregnant or lactating women;
 history of psychiatric disability judged by the
investigator to be clinically significant, precluding
informed consent or interfering with compliance for
HAIP chemotherapy;
 serious concomitant systemic disorders that would
compromise the safety of the patient or his/her
ability to complete the study, at the discretion of the
investigator;
 organ allografts requiring immunosuppressive
therapy;
 serious, non-healing wound, ulcer, or bone fracture;
 chronic treatment with corticosteroids;
 serious infections (uncontrolled or requiring
treatment);
 participation in another interventional study for
CRLM with survival as outcome;
 any psychological, familial, sociological, or
geographical condition potentially hampering
compliance with the study protocol and follow-up
schedule.
Treatment strategies
Standard procedures in control arm (arm A)
Patients included in the study should undergo surgery
within 6 weeks after signing the informed consent. Local
treatment (resection and/or open ablation) of the CRLM
in both arms is in accordance with the national guide-
lines. An intra-operative ultrasound evaluation of the
liver will be performed to assure the feasibility of
complete resection of the CRLM with an adequate liver
remnant. Resection of CRLM can be performed either
by minimal-invasive (laparoscopic or robotic) or open
approach at the discretion of the surgeon.
Investigational procedures of the experimental arm (arm
B)
The treatment of patients randomized to the experimen-
tal arm consists of HAI pump placement following
complete resection and/or open ablation of all CRLM.
Pump implantation will be cancelled in patients with un-
expected unresectable CRLM or EHD detected at the
time of surgery. Implantation of the HAI pump (Tri-
cumed IP2000V infusion pump; Fig. 2) is performed by
an open or minimal-invasive approach. In patients re-
quiring simultaneous resection of the primary tumor
and CRLM, the colorectal resection is performed after
pump placement to reduce the risk of pump contamin-
ation. The implantation procedure of the infusion pump
and dose adjustment protocols have been discussed by
Fig. 2 Tricumed infusion pump
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previous authors and was optimized for the materials
used in this trial [14, 15]. In addition to local treatment
of the CRLM, a cholecystectomy is performed to avoid
cholecystitis as a result of inadvertent intra-arterial
chemotherapy of the gallbladder [16]. The pump cath-
eter is positioned in the gastroduodenal artery (GDA)
allowing perfusion of the entire liver without obstructing
the flow in the hepatic artery. The pump catheter has
rings at the distal end that allow for securing the cath-
eter with non-absorbable ties in the GDA (Fig. 3). In pa-
tients with abnormal hepatic arterial anatomy, the GDA
is still the preferred site, as long as it connects with a
proper hepatic artery perfusing at least one segment of
the liver. Perfusion of the entire liver can be achieved in
these patients by ligating all accessory and replaced hep-
atic arteries. Intrahepatic shunts will typically reassure
that the catheter perfuses all liver segments.
The entire GDA and the proximal proper hepatic ar-
tery are mobilized and dissected circumferentially from
their attachments to facilitate insertion of the catheter
and to avoid inadvertent perfusion of the pancreas,
stomach, or duodenum. Branches to the retroperito-
neum arising from the right or left hepatic artery are
common and should be ligated. The use of papaverine is
optional to gain additional dilatation of the GDA.
Before implantation, a function test of the pump is
performed to confirm flow. The pump pocket should be
created in the left lower quadrant so that contact with
the anterior superior iliac spine and the lower ribs is
avoided. The pocket cavity should be 3/4 caudal to the
incision to ensure an optimal position of the septum for
refills. The catheter is tunneled through the abdominal
wall into the abdominal cavity. The pump is secured to
the abdominal fascia with nonabsorbable sutures; the
catheter should be positioned behind the pump to pre-
vent catheter injury by a needle when accessing the
pump percutaneously.
Next, the GDA is ligated with a nonabsorbable tie as
far away (at least 2 cm) from the common hepatic artery
as possible. Vascular control of the common and proper
hepatic arteries is achieved with vascular clamps or ves-
sel loops. Isolated vascular control of the GDA at its ori-
fice can be used alternatively to avoid occlusion of the
hepatic artery. A transverse arteriotomy is made in the
distal GDA, and the catheter is inserted up to but not
beyond the junction with the hepatic artery (Fig. 4). If
the catheter protrudes into the common hepatic artery,
turbulence of blood flow can lead to increased risk of
thrombosis of the hepatic artery. Failure to pass the
catheter to the junction leaves a short segment of the
GDA exposed to full concentrations of floxuridine with-
out the diluting effect of blood flow, potentially resulting
in sclerosis, thrombosis, pseudo-aneurysm with bleeding,
or late dislodgment. When positioned, the catheter
should be secured with three to four nonabsorbable ties
(silk 2.0) proximal to the tying rings on the catheter.
Perfusion of both lobes of the liver and lack of extrahe-
patic perfusion is confirmed by a bolus injection of
methylene blue. After the perfusion test, the catheter is
flushed with heparinized saline, and the wounds are
closed.
Postoperative procedures experimental arm
Prior to the first administration of intra-arterial chemo-
therapy, bilobar hepatic perfusion and lack of extrahe-
patic perfusion are confirmed by:
1. A multiphase or perfusion CT with contrast
injection through the bolus port of the pump.
2. Technetium-99-labeled macroaggregated albumin
(Tc-99 m MAA) scintigraphy. Tc-99 m MAA is ad-
ministered through the pump bolus port. Within 1
h after Tc-99M MAA injection, both planar im-
aging and a SPECT/CT scan are performed.
Patients with extrahepatic perfusion are evaluated an-
giographically and aberrant branches embolized with
re-testing prior to treatment.
Drug treatment plan experimental arm
The drug that is used for HAIP is floxuridine (also known
as fluorodeoxyuridine (FUDR), Fresenius Kabi, LLC,
USA). HAIP chemotherapy with floxuridine has been ad-
ministered since the early eighties for patients with CRLM
in the adjuvant, neo-adjuvant, and induction chemother-
apy setting [10, 16–24]. Floxuridine has a half-life of 10
min and the liver extracts 95% of floxuridine during the
first pass [8]. Toxic effects have been well characterized.
The pump reservoir is filled percutaneously with 0.12mg/
kg floxuridine together with 35,000U of heparin, 25mg of
dexamethasone, and enough normal saline for a total vol-
ume of 35mL. For patients who are more than 25% above
Fig. 3 Distal tip of the intra-arterial catheter
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ideal body weight, the actual dose of floxuridine is calcu-
lated by using a weight that averages the patient’s actual
weight and their ideal weight. Patients will have HAIP ad-
ministered in a 4-weeks-cycle, with a total of 6 cycles. On
day 1, the pump reservoir is filled with floxuridine, dexa-
methasone, and heparinized saline. On day 15, the pump
is emptied and refilled with heparinized saline (35,000 U
of heparin and enough normal saline for a total volume of
35mL) for 2 weeks. Until completion of HAIP chemother-
apy, patients will receive a prophylactic proton-pump in-
hibitor once daily. The use of NSAIDs is discouraged
during HAIP treatment. Patients’ complete blood counts
and liver tests are monitored every 2 weeks during HAIP
chemotherapy. In patients with abnormal liver values,
dose reduction or discontinuation of HAIP chemotherapy
is performed according to a predetermined protocol
(Table 1). Dexamethasone (25mg) is added to the hepa-
rinized saline in case of toxicity according to the values in
Table 1 resulting in cessation of floxuridine.
Follow-up
Follow-up for patients both randomized to arm A and
arm B will be performed with CEA measurement and
abdominal and chest CT including 4-phase liver imaging
(year 1–3: every 3 months; year 4–5: every 6 months).
The surgical complication score is measured 2 weeks
and 3 months after surgery. The chemotherapy toxicity
score is measured 2 weeks, three and 6 months after
surgery. Quality of life is measured in both arms at base-
line, every 3 months in the first year, and 2 and 5 years
after surgery.
Fig. 4 Intra-arterial positioning securing of distal tip of the catheter. Arrow: Tip of the catheter is positioned at the orifice of the GDA
Table 1 Dose adjustment schedule
Reference Value (RV)a
Upper limit of normal
% floxuridine dose
Aspartate aminotransferase 2–3 a RV 80%
3–4 a RV 50%
> 4 a RV Hold
Alkaline phosphatase 1.2–1.5 a RV 50%
> 1.5 a RV Hold
Total bilirubin 1.2–1.5 a RV 50%
> 1.5 a RV Hold
aReference value is defined as the patient’s value on the first day of the most
recent floxuridine dose
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Study endpoints and analyses
Primary endpoint
Primary endpoint of this study will be PFS, calculated
from the time between surgery and the first event defined
as recurrence or death or last follow-up. Patients still alive
without recurrence at last contact are censored.
Analysis of the primary endpoint
The formal test for difference in PFS between the two
treatment arms will be done with a multivariate Cox re-
gression analysis with adjustment for the stratification
factor except hospital. The actuarial method of Kaplan
and Meier will be used to estimate survival probabilities,
while the Greenwood estimate will be used to construct
corresponding 95% confidence intervals (CIs). Kaplan-
Meier curves will be generated to illustrate PFS, for all
patients as well as by treatment arm. A prespecified sub-
group analysis will be performed for the following sub-
groups: node-negative CRC, CRS of 0 to 1 points, and
KRAS wild-type.
Secondary endpoints
Secondary endpoints include: OS (calculated from
surgery until death from any cause; patients still alive
at last contact are censored), hepatic PFS, safety,
quality of life (EQ-5D + QCQ-C30), and cost-effective-
ness. Furthermore, the pharmacokinetic profile of
intra-arterial administration of floxuridine will be in-
vestigated in more detail. Moreover, we aim to iden-
tify predictive biomarkers (circulating tumor DNA)
for the efficacy of HAIP chemotherapy. Finally, the
accuracy of CT angiography will be evaluated com-
pared to radionuclide scintigraphy to detect extrahe-
patic perfusion.
Sample size calculation
A median PFS of 17 months was observed in 228
low-risk patients with resectable CRLM at Erasmus MC
treated between 2000 and 2012, without EHD (consist-
ent with arm A). In a multivariable analysis using a con-
secutive cohort of 779 low-risk patients without EHD,
treated with or without HAIP chemotherapy between
2000 and 2012 at MSKCC, a hazard ratio (HR) of 0.60
(95% CI: 0.49–0.75) was found. Given a HR of 0.60 (cor-
responding to a median PFS of 28 months in arm B),
80% power and a 2-sided significance level α = 0.05, a
total of 126 events need to be observed. With an ex-
pected accrual rate of 6 patients per month in five cen-
ters, 3 years accrual and one additional year of
follow-up, and taking into account a drop-out rate of
5%, a total of 230 patients need to be randomized. No
interim analysis is planned for survival outcomes.
Safety analysis
Interim analyses are performed for postoperative com-
plications (grade 3 or higher) and adverse events (serious
adverse events plus adverse events of grade 3 or higher)
for early detection of unusually high rates of complica-
tions and adverse events in the experimental arm (arm
B). Interim analyses are planned after inclusion of 20
and 50 patients in arm B.
Discussion
In this trail patients receive adjuvant HAIP chemother-
apy without systemic chemotherapy. HAIP chemother-
apy in MSKCC is always combined with concurrent
adjuvant systemic chemotherapy. Adjuvant systemic
chemotherapy is currently not recommended in Dutch
guidelines for patients who underwent complete resec-
tion of CRLM, since no difference in OS was found in a
large RCT [3, 4]. Some retrospective studies confirmed
that adjuvant systemic chemotherapy has no impact on
OS in patients with a low CRS [25–27].
A previous RCT from MSKCC, which compared pa-
tients who received adjuvant systemic 5-fluorouracil
(5-FU) and HAIP chemotherapy with patients who
received systemic 5-FU alone demonstrated a beneficial
2-years OS of 85% with HAIP versus 69% with 5-FU
alone (p = 0.02) [10]. Despite this result, HAIP chemo-
therapy has not been widely adopted. The NCCN guide-
lines recommend adjuvant HAIP chemotherapy for
CRLM as an option in experienced centers (Category
2B). A retrospective study from MSKCC demonstrated a
superior OS of 23 months (67 months versus 44 months)
in patients treated with HAIP and concurrent systemic
chemotherapy compared to systemic chemotherapy
alone in patients with resectable CRLM. These results
have renewed interest in HAIP chemotherapy outside
MSKCC [28]. Another phase III RCT is required to
compare adjuvant HAIP chemotherapy for CRLM with
surgery alone. The PUMP trial aims to definitively eluci-
date the efficacy of adjuvant HAIP chemotherapy in pa-
tients with resectable CRLM.
Only low-risk patients without EHD will be eligible for
inclusion in the PUMP trial. This subgroup demon-
strated to benefit more (median OS 89months versus
53months, p < 0.001) compared to high-risk patients
(median OS 50 months versus 35 months, p < 0.001).
Furthermore, no survival benefit was found in patients
with EHD prior to or at time of resection (median OS
37months versus 33months, p = 0.92). These results
have determined the study design and sample size calcu-
lation for the PUMP trial.
HAIP chemotherapy requires a well-trained large
multidisciplinary team. A previous RCT investigating
intra-arterial chemotherapy for CRLM, performed in 26
centers in Germany, was terminated early due to high
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complication rates [29]. Therefore, we comprehensively
trained and proctored the five multidisciplinary teams
participating in the PUMP trial. Moreover, a pilot study
prior to the RCT has been conducted to confirm the
safety and feasibility.
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